Gail MD - Aclaris Therapeutics Chief Officer
| ACRS Stock | USD 4.32 0.36 9.09% |
Executive
Gail MD is Chief Officer of Aclaris Therapeutics
| Age | 61 |
| Address | 701 Lee Road, Wayne, PA, United States, 19087 |
| Phone | 484 324 7933 |
| Web | https://www.aclaristx.com |
Aclaris Therapeutics Management Efficiency
The company has return on total asset (ROA) of (0.1939) % which means that it has lost $0.1939 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.2583) %, meaning that it created substantial loss on money invested by shareholders. Aclaris Therapeutics' management efficiency ratios could be used to measure how well Aclaris Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.47 in 2024. Return On Capital Employed is likely to drop to -0.61 in 2024. At this time, Aclaris Therapeutics' Non Current Assets Total are comparatively stable compared to the past year. Total Current Assets is likely to gain to about 139.1 M in 2024, whereas Other Current Assets are likely to drop slightly above 7.2 M in 2024.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Sarah Demey | Neogen | N/A | |
| Jessica Olbricht | Biodesix | N/A | |
| Andrea Spannheimer | IQVIA Holdings | N/A | |
| Fernando Beils | Qiagen NV | N/A | |
| Joseph Vitale | Sotera Health Co | N/A | |
| Antonio Santos | Qiagen NV | N/A | |
| Mark DeBlock | Biodesix | N/A | |
| MA BSN | Medpace Holdings | 61 | |
| Nigel Clerkin | ICON PLC | 50 | |
| Joel Neoh | Prenetics Global | 40 | |
| Kathleen Hoffman | Sotera Health Co | N/A | |
| Alice Izzo | Castle Biosciences | N/A | |
| Yung DPHIL | Prenetics Global | 42 | |
| Thomas Neidert | Qiagen NV | N/A | |
| Elizabeth Tallett | Qiagen NV | 71 | |
| Kieran OKane | Biodesix | 47 | |
| Justin Hunter | Myriad Genetics | N/A | |
| Lucas Glass | IQVIA Holdings | N/A | |
| Hoi Lo | Prenetics Global | 39 | |
| Nigel ACA | ICON PLC | 50 | |
| Reinilde MD | Medpace Holdings | 63 | |
Management Performance
| Return On Equity | -0.26 | ||||
| Return On Asset | -0.19 |
Aclaris Therapeutics Leadership Team
Elected by the shareholders, the Aclaris Therapeutics' board of directors comprises two types of representatives: Aclaris Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Aclaris. The board's role is to monitor Aclaris Therapeutics' management team and ensure that shareholders' interests are well served. Aclaris Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Aclaris Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Neal DO, President, CoFounder | ||
| Frank Ruffo, CFO CoFounder | ||
| Joseph Monahan, Chief Officer | ||
| Gail MD, Chief Officer | ||
| Robert Doody, VP Relations | ||
| MD DO, President CoFounder | ||
| Matthew JD, General Secretary | ||
| MD Frcp, Pres COO | ||
| Kevin Balthaser, Chief Officer | ||
| MD MBA, Senior Development | ||
| Steve Tucker, Senior Leadership | ||
| Ian Anderson, Ex RD | ||
| Jon Jacobsen, Senior Chemistry | ||
| James Loerop, Chief Officer | ||
| Paul Changelian, VP Biology |
Aclaris Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Aclaris Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.26 | ||||
| Return On Asset | -0.19 | ||||
| Profit Margin | (1.37) % | ||||
| Operating Margin | (2.23) % | ||||
| Current Valuation | 189.9 M | ||||
| Shares Outstanding | 71.43 M | ||||
| Shares Owned By Insiders | 2.65 % | ||||
| Shares Owned By Institutions | 73.53 % | ||||
| Number Of Shares Shorted | 2.41 M | ||||
| Price To Earning | (12.14) X |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Aclaris Stock Analysis
When running Aclaris Therapeutics' price analysis, check to measure Aclaris Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Aclaris Therapeutics is operating at the current time. Most of Aclaris Therapeutics' value examination focuses on studying past and present price action to predict the probability of Aclaris Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Aclaris Therapeutics' price. Additionally, you may evaluate how the addition of Aclaris Therapeutics to your portfolios can decrease your overall portfolio volatility.